With a new month upon us, I think it could be a good time to take a look at your portfolio and see if it needs some adjustments.
If you're looking for some growth shares to buy, then the three listed below could be great options in August. Here's why I like them:
Altium Limited (ASX: ALU)
Altium is a printed circuit board (PCB) design software provider which I think would be a great long term option for investors. As PCBs are found inside almost all connected devices, I believe Altium is a great way to gain exposure to the Internet of Things boom. A boom which I expect to accelerate when 5G internet becomes the norm. The explosive speeds of 5G internet should allow more and more everyday devices to connect to the internet, which could lead to an increase in licenses for its award-winning Altium Designer software. The launch of its cloud-based Altium 365 offering also looks likely to be a key driver of growth in the coming years.
Appen Ltd (ASX: APX)
I think this global leader in the development of high-quality, human-annotated training data for machine learning and artificial intelligence would also be a great long-term investment option. Appen has been growing at an impressively strong rate in recent years thanks to the growth in machine learning and artificial intelligence and its leadership position in data annotation. As this market is expected to continue growing materially over the next decade, I feel Appen is well-placed to continue its strong form long into the future.
ResMed Inc. (ASX: RMD)
Another growth share to consider buying in August is ResMed. I'm a big fan of this sleep treatment products developer and believe its shares could provide outsized returns for investors over the next decade. This is thanks to the quality of its products and its growing addressable market. In respect to the latter, management estimates that there are 1 billion people impacted by sleep apnoea worldwide. However, the vast majority of these sufferers are currently undiagnosed and could be at risk of life-threatening conditions. I expect the growing education around sleep disorders to lead to more diagnoses and support ResMed's growth over the coming years.
